Clinical trials: Diabetes, Type 1
Type 1 Diabetes Mellitus
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to <18 years old with newly diagnosed…
- Trial name
- INHALE-1st (NCT07224321)
- Testing
- Technosphere Insulin, Basal insulin
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mannkind Corporation
Type 1 Diabetes Mellitus
Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes
The purpose of this study is to determine whether intravenous administration of autologous adipose stem cells is safe and beneficial in patients with type 1 diabetes.
- Trial name
- NCT00703599
- Testing
- Autologous Adipose-derived Stem cells
- Where
- 2 sites in Philippines
- Volunteers
- 30 people
- Sponsor
- Adistem Ltd
Diabetes Mellitus, Type 1
IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)
The IMPACT study is a study to test a new experimental drug, IMCY-0098, for the treatment of type 1 diabetes (T1D). In most people with type 1 diabetes, the pancreas loses its ability to make insulin because some cells of the…
- Trial name
- IMPACT (NCT04524949)
- Testing
- IMCY-0098 450 μg, IMCY-0098 1350 μg
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Imcyse SA
Diabetes, Diabetes Mellitus, Type 1
A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
This is an inpatient treatment, double-blind, randomized, 3-way crossover study in T1DM subjects using insulin pump therapy.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
- Trial name
- NCT04956263
- Testing
- YG1699, Dapagliflozin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Youngene Therapeutics Inc., Ltd.
Diabetic Foot Ulcer
Blue Light Photobiomodulation Therapy on Neuroischemic Patients
This is a pilot case/control clinical study on a group of outpatients with diabetic foot lesions aiming to verify the efficacy and safety of the Blue light photobiomodulation therapy with EmoLED medical device, in addition to…
- Trial name
- HERMES (NCT04831606)
- Testing
- debridement, Offloading, Advanced dressing
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Emoled
Diabetes Mellitus, Type 1
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D.
- Trial name
- NCT06588504
- Testing
- Dasiglucagon, Glucagon
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Advanced or Metastatic Solid Tumor Malignancies
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally…
- Trial name
- NCT06258304
- Testing
- GIGA-564
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- GigaGen, Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate…
- Trial name
- NCT03216226
- Testing
- dasiglucagon, GlucaGen
- Where
- 7 sites in United States, Austria and 2 more
- Volunteers
- 112 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
- Trial name
- NCT04585776
- Testing
- LY900014, Insulin Degludec
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients
Primary Objective: To assess the tolerability and safety of SAR438544 after single ascending subcutaneous (SC) doses in healthy subjects and in type 1 diabetes mellitus (T1DM) patients.
- Trial name
- NCT02625636
- Testing
- SAR438544, r-glucagon
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the Safety, Tolerability,Pharmacokinetics (the exposure of the trial drug in the body) and Pharmacodynamics (the effect of the investigated drug on the…
- Trial name
- NCT02612844
- Testing
- NNC0143-0406, insulin aspart
- Where
- Austria
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients
The purpose of this study is to determine if the combination of oral cyclosporine, an immune therapy and oral omeprazole, a proton pump inhibitor, are effective in rendering insulin independence among recent onset type 1 diabetes…
- Trial name
- IIT (NCT01762644)
- Testing
- Oral Cyclosporine and Oral Omeprazole, Oral Omeprazole
- Sponsor
- Perle Bioscience, Inc.
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
This study is conducted in Asia. The aim of this observational study is to investigate the clinical safety profile and effectiveness while using SC NovoRapid™ (insulin aspart) in patients with coexisting diabetes and kidney…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Kidney Disease
- Trial name
- NCT00849316
- Testing
- insulin aspart
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate steady state pharmacokinetics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.
- Trial name
- NCT01524809
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
- Trial name
- NCT03538743
- Testing
- PF-06882961
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Primary Objective: To evaluate the efficacy of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone in terms of glycemic control as reflected by HbA1c during a…
- Trial name
- NCT01457911
- Testing
- Glimepiride and Metformin hydrochloride combination (HOE490), Glimepiride (HOE490)
- Where
- 22 sites in China
- Volunteers
- 244 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- BEGIN™ (NCT01079234)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 82 sites in United States, Belgium and 5 more
- Volunteers
- 493 people
- Sponsor
- Novo Nordisk A/S
Patients
Drug Interaction Study Between Dorzagliatin and Sitagliptin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM.
- Trial name
- NCT03790839
- Testing
- Sitagliptin, Dorzagliatin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hua Medicine Limited
Obesity & Overweight, Type 2 Diabetes
A Food-Effect Study of CX11 in Healthy Participants
This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants
- Trial name
- NCT07349381
- Testing
- CX11 (VCT220)
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.